Abstrakt

Clinical study of advances in immunotherapy for kaposi sarcoma.

Guven Aksoy*

Immunotherapy has emerged as a promising treatment approach for KS, harnessing the body's immune system to target the Human Herpesvirus 8 (HHV-8) and abnormal blood vessels associated with the disease. Key immunotherapeutic strategies include immune checkpoint inhibitors, cytokine therapy, and targeted therapies. Clinical studies have demonstrated encouraging results, with durable responses and improved overall survival rates in refractory KS patients. However, challenges such as patient selection, management of immune-related adverse events, and optimal combination strategies need to be addressed. Future research directions include the development of predictive biomarkers, exploration of combination approaches, and long-term follow-up studies. Immunotherapy offers new hope for patients with KS and has the potential to transform the landscape of care.